This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by KOSOWSKY, B. D. Articles by RITCHIE, R. F. Search for Related Content PubMed PubMed Citation Articles by KOSOWSKY, B. D. Articles by RITCHIE, R. F.

(Circulation. 1973;47:1204.)
© 1973 American Heart Association, Inc.

---

Long-Term Use of Procaine Amide following Acute Myocardial Infarction

BERNARD D. KOSOWSKY M.D.¹; JACK TAYLOR M.D.¹; BERNARD LOWN M.D.¹; ROBERT F. RITCHIE M.D.¹

¹ From the Cardiovascular Research Laboratories, Department of Nutrition, Harvard School of Public Health; and the Levine Cardiac Unit, Cardiovascular Division, Department of Medicine, Peter Bent Brigham Hospital, Boston, Massachusetts.

The safety of long-term prophylactic antiarrhythmic therapy with procaine amide was studied in 78 patients recovering from acute myocardial infarction. Patients were randomly allocated to a control or treatment group and followed monthly for up to 2 years with ambulatory ECG monitoring and measurement of serum drug level, antinuclear antibody (ANA) titer, LE preparation, blood count, BUN, and SGOT. Early reactions forced discontinuation of therapy in nine of 39 treated patients within the first 3 weeks. Late reactions were observed in 14 of 16 patients who took procaine amide for 3 months or longer. Every patient on therapy for 1 year or longer demonstrated elevation in ANA titer. Comparison of monitoring data between these two groups revealed no difference in the incidence of occasional or frequent premature ventricular beats. However, during the first 6 months, treated patients tended to have fewer major arrhythmias. There were fewer sudden deaths among treated patients, but this difference did not reach statistical significance at the 5% level. It is concluded that the high incidence of toxic reactions precludes widespread use of long-term prophylactic procaine amide therapy. More precise identification of a sudden death-prone population might justify such therapy in such selected cases.

Key Words: Antiarrhythmic therapy • Lupus erythmatosis • Ventricular premature beats • Sudden death

Submitted on October 19, 1972
Accepted on February 27, 1973

This article has been cited by other articles:

				E. J. Stanek, M. D. Schoen, and J. L. Bauman Issues in the Treatment of Ventricular Ectopy: Past, Present, and Future Controversy Journal of Pharmacy Practice, January 1, 1990; 3(5): 283 - 294. [PDF]

				J. Speer Schroeder Newer Antiarrhythmic Agents for Patients With Coronary Artery Disease Angiology, January 1, 1978; 29(1): 22 - 32. [PDF]